KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 42.82%.

  • Gilead Sciences' EBITDA Margin rose 310500.0% to 42.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.06%, marking a year-over-year increase of 331600.0%. This contributed to the annual value of 5.78% for FY2024, which is 222700.0% down from last year.
  • Gilead Sciences' EBITDA Margin amounted to 42.82% in Q3 2025, which was up 310500.0% from 34.93% recorded in Q2 2025.
  • Over the past 5 years, Gilead Sciences' EBITDA Margin peaked at 51.77% during Q3 2021, and registered a low of 64.64% during Q1 2024.
  • Over the past 5 years, Gilead Sciences' median EBITDA Margin value was 32.41% (recorded in 2022), while the average stood at 25.95%.
  • In the last 5 years, Gilead Sciences' EBITDA Margin crashed by -914800bps in 2024 and then soared by 982000bps in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' EBITDA Margin stood at 12.98% in 2021, then soared by 136bps to 30.68% in 2022, then decreased by -26bps to 22.66% in 2023, then surged by 43bps to 32.4% in 2024, then surged by 32bps to 42.82% in 2025.
  • Its EBITDA Margin was 42.82% in Q3 2025, compared to 34.93% in Q2 2025 and 33.55% in Q1 2025.